文献速递糖尿病

长期补充维生素D与n-3脂肪酸对2型糖尿病患者炎症及心脏生物标志物的影响:随机对照试验二次分析

Effects of long-term vitamin D and n-3 fatty acid supplementation on inflammatory and cardiac biomarkers in patients with type 2 diabetes: secondary analyses from a randomised controlled trial.
PubMed 文献 · Diabetologia · 2020-10-24

本研究为随机对照试验的预设二次分析,纳入1312例无心血管疾病、恶性肿瘤或终末期肾病的2型糖尿病成人,采用2×2析因设计比较维生素D3(2000 IU/天)和/或n-3脂肪酸(EPA+DHA 1 g/天)与安慰剂对5年血清IL-6、hsCRP和NT-proBNP变化的影响。结果显示,与安慰剂相比,维生素D3组NT-proBNP5年升高幅度增加1.24倍(95%CI 1.09,1.41;p=0.003),而IL-6和hsCRP变化无显著差异;n-3脂肪酸对三种标志物变化均无显著影响。结论认为,在2型糖尿病成人中补充维生素D3或n-3脂肪酸未降低IL-6、hsCRP或NT-proBNP。

要点

  • 维生素D3补充使NT-proBNP5年升高幅度较安慰剂增加1.24倍(95%CI 1.09,1.41;p=0.003)。
  • 维生素D3或n-3脂肪酸对IL-6和hsCRP的5年变化无显著影响。
  • n-3脂肪酸对IL-6、hsCRP或NT-proBNP的5年变化均无显著影响。

核心结论

  • 在2型糖尿病成人中,补充维生素D3或n-3脂肪酸未降低IL-6、hsCRP或NT-proBNP。
  • 维生素D3组NT-proBNP5年升高幅度显著大于安慰剂组。

研究设计与样本

  • 研究为随机对照试验的预设二次分析,纳入1312例无已知心血管疾病、恶性肿瘤或终末期肾病的2型糖尿病成人。
  • 采用2×2析因设计,随机分配至维生素D3(2000 IU/天)或安慰剂及n-3脂肪酸(EPA+DHA 1 g/天)或安慰剂。
  • 参与者、检查者和结果评估研究者对干预分配设盲,在基线、2年和5年测量血清IL-6、hsCRP和NT-proBNP。

主要发现

  • 共333例分配至维生素D3加n-3脂肪酸安慰剂,289例至n-3脂肪酸加维生素D3安慰剂,370例至维生素D3加n-3脂肪酸,320例至双安慰剂。
  • 989例(75%)在2年、934例(71%)在5年返回血样;参与者平均年龄67.6岁(46%女性)。
  • 基线IL-6、hsCRP和NT-proBNP几何均值分别为1.2 pg/ml、1.9 mg/l和262 ng/l。
  • 5年后平均IL-6和hsCRP保持在基线值6%以内,而平均NT-proBNP总体升高55%。
  • 与安慰剂相比,维生素D3组NT-proBNP5年升高幅度增加1.24倍(95%CI 1.09,1.41;p=0.003),IL-6和hsCRP变化无显著差异;n-3脂肪酸与安慰剂相比,IL-6、hsCRP或NT-proBNP变化均无显著差异。

关键数值与推荐

  • 维生素D3剂量为2000 IU/天,n-3脂肪酸剂量为EPA+DHA 1 g/天。
  • 维生素D3组NT-proBNP5年变化较安慰剂组高1.24倍(95%CI 1.09,1.41;p=0.003)。
  • 亚组分析(基线eGFR、尿白蛋白肌酐比、初始生物标志物浓度、25-羟基维生素D水平或EPA+DHA指数)未观察到异质性。

临床怎么用

  • 对于2型糖尿病成人,长期补充维生素D3或n-3脂肪酸未显示降低IL-6、hsCRP或NT-proBNP的获益。
  • 维生素D3补充与NT-proBNP升高相关,临床解读NT-proBNP时应考虑补充剂使用情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Interventions that reduce inflammation may delay progression of microvascular and macrovascular complications in diabetes. We examined the effects of vitamin D3 and/or n-3 fatty acid supplementation vs placebo on 5 year changes in serum inflammatory and cardiac biomarkers in adults with type 2 diabetes. METHODS: This study reports pre-specified secondary outcomes of the Vitamin D and Omega-3 Trial to Prevent and Treat Diabetic Kidney Disease, in which 1312 US adults with type 2 diabetes and without known cardiovascular disease, malignancy, or end-stage kidney disease were randomised using computer-generated random numbers in blocks of eight to vitamin D3 (2000 IU/day) vs placebo and n-3 fatty acids (eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]; 1 g/day) vs placebo in a 2 × 2 factorial design. Participants, examiners, and researchers assessing outcomes were blinded to intervention assignment. We measured serum IL-6, high-sensitivity C-reactive protein (hsCRP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) at baseline and after 2 and 5 years. RESULTS: A total of 333 participants were randomised to vitamin D3 and placebo n-3 fatty acids, 289 to n-3 fatty acids and placebo vitamin D3, 370 to vitamin D3 and n-3 fatty acids, and 320 to 2 placebos; 989 (75%) and 934 (71%) participants returned blood samples at 2 and 5 years, respectively. Participants had a mean age of 67.6 years (46% women). Overall, baseline geometric means of IL-6, hsCRP and NT-proBNP were 1.2 pg/ml, 1.9 mg/l and 262 ng/l, respectively. After 5 years, mean IL-6 and hsCRP remained within 6% of their baseline values while mean NT-proBNP increased by 55% overall. Compared with placebo, participants assigned to vitamin D3 had a 1.24-fold greater increase in NT-proBNP over 5 years (95% CI 1.09, 1.41; p = 0.003), while IL-6 and hsCRP did not have a significant difference in change. Comparing n-3 fatty acids with placebo, there was no significant difference in change in IL-6, hsCRP or NT-proBNP. No heterogeneity was observed in subgroup analyses accounting for baseline eGFR, urine albumin to creatinine ratio, initial biomarker concentration, 25-hydroxyvitamin D level or EPA+DHA index. CONCLUSIONS/INTERPRETATION: Among adults with type 2 diabetes, supplementation with vitamin D3 or n-3 fatty acids did not reduce IL-6, hsCRP or NT-proBNP over 5 years. TRIAL REGISTRATION: ClinicalTrials.gov NCT01684722 FUNDING: The study was funded by grant R01DK088762 from the National Institute of Diabetes and Digestive and Kidney Diseases. Graphical abstract.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Limonte CP, Zelnick LR, Ruzinski J, et al. Effects of long-term vitamin D and n-3 fatty acid supplementation on inflammatory and cardiac biomarkers in patients with type 2 diabetes: secondary analyses from a randomised controlled trial. Diabetologia. 2020. PMID: 33098434. doi:10.1007/s00125-020-05300-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。